SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Pharma Science surges as its Stelis commissions greenfield vaccine manufacturing facility at Bengaluru

21 Dec 2021 Evaluate

Strides Pharma Science is currently trading at Rs. 423.00, up by 11.10 points or 2.69% from its previous closing of Rs. 411.90 on the BSE.

The scrip opened at Rs. 426.50 and has touched a high and low of Rs. 426.50 and Rs. 420.50 respectively. So far 5923 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1000.00 on 08-Jan-2021 and a 52 week low of Rs. 403.55 on 20-Dec-2021.

Last one week high and low of the scrip stood at Rs. 497.35 and Rs. 403.55 respectively. The current market cap of the company is Rs. 3698.15 crore.

The promoters holding in the company stood at 29.60%, while Institutions and Non-Institutions held 45.40% and 25.00% respectively.

Strides Pharma Science’s biotech division -- Stelis Biopharma (Stelis) has commissioned its large-scale fully integrated vaccine manufacturing facility at Bengaluru, India. The facility was successfully inspected by the Central Drugs Standard Control Organization (CDSCO). Stelis has also received an initial Export No Objection Certificate (NOC) from CDSCO to export up to 50 million doses of the Sputnik Light vaccine.

Stelis' greenfield vaccine facility was built in a record time of less than 200 days with a best in class design and modularity to cater to several vaccine formats. It is also one of the largest viral vector manufacturing sites with a bespoke design for producing the Russian Sputnik Vaccine.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×